12
Nov

Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France’s Servier.

…read more

Source: Servier gambling up to $1B-plus on Intarcia’s PhIII diabetes drug/device

    

0 No comments